Suppliers and packagers for EXJADE

EXJADE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882	NDA	Novartis Pharmaceuticals Corporation	0078-0468-15	30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0468-15)	2005-11-30
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882	NDA	Novartis Pharmaceuticals Corporation	0078-0469-15	30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0469-15)	2005-11-30
Novartis	EXJADE	deferasirox	TABLET, FOR SUSPENSION;ORAL	021882	NDA	Novartis Pharmaceuticals Corporation	0078-0470-15	30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0470-15)	2005-11-30

Exjade (Deferasirox) API Suppliers and Manufacturing Landscape

Last updated: February 19, 2026

This report details the current landscape of suppliers for the active pharmaceutical ingredient (API) deferasirox, the key component of the drug Exjade. It analyzes manufacturing capabilities, regulatory compliance, and market dynamics impacting the supply chain.

Who are the Key Manufacturers of Deferasirox API?

The production of deferasirox API is concentrated among a limited number of global manufacturers, primarily located in India and China. These companies possess the specialized chemical synthesis capabilities and regulatory track record required for pharmaceutical ingredient production.

• Key Manufacturers Identified:
  • Cipla Limited (India): A major Indian pharmaceutical company with established capabilities in complex API synthesis. Cipla is a significant supplier for various generic drug markets, including deferasirox.
  • Lupin Limited (India): Another leading Indian pharmaceutical firm known for its API manufacturing capacity and a broad portfolio of generic products. Lupin has demonstrated its ability to produce deferasirox API meeting stringent quality standards.
  • Sun Pharmaceutical Industries Ltd. (India): As one of the largest generic pharmaceutical companies globally, Sun Pharma has extensive manufacturing infrastructure and expertise in API production, including deferasirox.
  • Dr. Reddy's Laboratories (India): A well-recognized player in the global API market, Dr. Reddy's is involved in the production of deferasirox API, serving both its internal needs and external markets.
  • Zydus Lifesciences (formerly Cadila Healthcare) (India): Zydus has a robust API manufacturing division and is capable of producing deferasirox for global distribution.
  • Hospira, Inc. (now part of Pfizer) (USA/Global): While primarily known for finished dosage forms, Hospira, and now Pfizer, has had involvement in the supply chain, though direct API manufacturing might be outsourced or integrated differently.
  • Various Chinese Manufacturers (Unspecified but significant): Numerous Chinese chemical and pharmaceutical companies are active in API production. While specific company names for deferasirox API are less publicly disclosed due to competitive reasons, China remains a critical manufacturing hub for many APIs, including those for iron chelators. These manufacturers often operate under strict quality agreements with their downstream pharmaceutical clients.

What are the Regulatory Requirements for Deferasirox API Production?

Manufacturing deferasirox API necessitates adherence to stringent global regulatory standards to ensure product quality, safety, and efficacy.

• Current Good Manufacturing Practices (cGMP): All manufacturing sites must comply with cGMP guidelines as stipulated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. This includes rigorous control over raw materials, production processes, facility maintenance, and quality control testing.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically file DMFs (in the US) or ASMFs (in Europe) with regulatory authorities. These confidential documents contain detailed information about the API's manufacturing process, controls, and specifications. Pharmaceutical companies reference these filings in their drug product applications.
• Impurity Profiling and Control: Manufacturers must meticulously identify, quantify, and control impurities, including residual solvents, heavy metals, and process-related byproducts. Specific limits for known and unknown impurities are set and monitored. For deferasirox, particular attention is paid to any potentially genotoxic impurities arising from the synthesis pathway.
• Stability Studies: Comprehensive stability testing is required to determine the shelf-life of the API under various storage conditions. This data is critical for ensuring the API remains within its specified quality attributes throughout its intended storage period.
• Site Inspections and Audits: API manufacturing facilities are subject to regular inspections by regulatory agencies and periodic audits by the pharmaceutical companies that purchase the API. These assessments verify ongoing compliance with cGMP and other relevant regulations.
• REACH Compliance (for European Market): Manufacturers exporting to the European Union must ensure their substances comply with Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations, particularly concerning the registration and safe use of chemical substances.

What is the Market Status and Outlook for Deferasirox API?

The market for deferasirox API is driven by the demand for Exjade and its generic equivalents, primarily used for treating chronic iron overload.

• Market Drivers:

  • Prevalence of Thalassemia and Sickle Cell Disease: These genetic blood disorders necessitate frequent blood transfusions, leading to iron overload, a primary indication for deferasirox. The global prevalence of these conditions directly impacts API demand.
  • Increased Access to Generic Medications: The expiration of key patents for Exjade has opened the market to generic manufacturers, increasing competition and driving down prices. This expansion in generic availability boosts API volumes.
  • Advancements in Disease Management: Improved diagnosis and management of iron overload conditions contribute to a larger patient population seeking treatment.
  • Emerging Markets: Growing healthcare infrastructure and increased affordability in emerging economies are expanding the market for both branded and generic iron chelation therapies.

• Market Challenges:

  • Price Sensitivity: The generic nature of the market leads to significant price pressure on API manufacturers. Cost-effective production and supply chain efficiency are paramount.
  • Regulatory Hurdles for New Entrants: Navigating the complex regulatory landscape and establishing the necessary DMFs/ASMFs can be a barrier to entry for new API manufacturers.
  • Supply Chain Disruptions: Geopolitical events, raw material availability fluctuations, and logistical challenges can impact API supply stability.
  • Competition from Alternative Therapies: While deferasirox is a dominant therapy, ongoing research into alternative or improved iron chelation methods could influence future market dynamics.

• Outlook: The market for deferasirox API is expected to remain stable with moderate growth. The established demand from chronic iron overload conditions, coupled with the ongoing expansion of generic drug access, will sustain this demand. Manufacturers focusing on quality, cost-efficiency, and reliable supply chains will be best positioned.

What are the Key Supply Chain Considerations for Pharmaceutical Companies?

Pharmaceutical companies sourcing deferasirox API must manage a complex supply chain to ensure consistent product availability and quality.

• Supplier Qualification and Auditing: Rigorous vetting of potential API suppliers is essential. This includes assessing their regulatory compliance, manufacturing capabilities, quality control systems, and financial stability. Regular on-site audits are critical for ongoing quality assurance.
• Geographic Diversification of Supply: Relying on a single supplier or a single geographic region poses significant risks. Companies should aim to establish relationships with multiple qualified suppliers across different regions to mitigate supply chain disruptions.
• Quality Agreements: Comprehensive quality agreements between the API manufacturer and the finished dosage form manufacturer are critical. These agreements define responsibilities, specifications, change control procedures, and notification requirements.
• Intellectual Property and Patent Landscape: While the primary composition-of-matter patents for deferasirox have expired in major markets, companies must remain aware of any potential secondary patents (e.g., process patents, formulation patents) that could affect manufacturing or market entry.
• Cost Management and Negotiating Power: The competitive landscape of generic APIs allows for negotiation. Companies must balance cost considerations with the imperative of maintaining high-quality standards and reliable supply. Bulk purchasing agreements and long-term contracts can offer cost benefits.
• Regulatory Filings and Approvals: Pharmaceutical companies must ensure that their chosen API suppliers have the necessary regulatory filings (DMFs/ASMFs) in place and that these are acceptable to the regulatory authorities in their target markets. Changes to API manufacturing processes often require regulatory notification or approval.
• Inventory Management: Maintaining adequate inventory levels of API is crucial to buffer against potential supply chain disruptions, production delays, or unexpected demand spikes. Just-in-time strategies may be too risky for critical APIs like deferasirox.
• Sustainability and Ethical Sourcing: Increasingly, pharmaceutical companies are expected to consider the environmental and ethical practices of their suppliers, including labor practices and environmental impact.

What are the Potential Risks and Mitigation Strategies?

Supply chain risks for deferasirox API are multifaceted, requiring proactive management.

• Risk: Regulatory Non-Compliance of API Manufacturer.
  • Mitigation: Conduct thorough due diligence on regulatory history. Implement robust quality agreements and monitor regulatory updates. Perform regular audits. Diversify suppliers to reduce reliance on a single potentially non-compliant entity.
• Risk: Raw Material Shortages or Price Volatility.
  • Mitigation: Secure multiple sources for key starting materials. Explore forward contracts for critical raw materials. Maintain strong relationships with suppliers to gain early insights into potential shortages.
• Risk: Geopolitical Instability or Natural Disasters Affecting Manufacturing Regions.
  • Mitigation: Geographic diversification of manufacturing sites. Maintain safety stock of finished goods and API. Develop contingency plans for alternative logistics routes.
• Risk: Quality Control Failures or Impurity Issues.
  • Mitigation: Establish stringent incoming quality control testing for API batches. Mandate comprehensive impurity profiling by the supplier. Implement rigorous analytical method validation. Consider dual sourcing from manufacturers with impeccable quality records.
• Risk: Patent Infringement (Secondary Patents).
  • Mitigation: Conduct freedom-to-operate analyses for manufacturing processes. Work with legal counsel specializing in pharmaceutical IP. Ensure API suppliers are aware of and comply with relevant process patent landscapes.
• Risk: Loss of Key Personnel or Technical Expertise at API Supplier.
  • Mitigation: Ensure robust knowledge transfer and documentation practices at the supplier. Build relationships with multiple technical contacts within the supplier organization.
• Risk: Intellectual Property Theft or Data Security Breaches at Supplier.
  • Mitigation: Include stringent IP protection clauses in supply agreements. Assess the cybersecurity measures of potential suppliers. Conduct due diligence on their data handling policies.

Key Takeaways

The supply chain for deferasirox API is dominated by established Indian and Chinese manufacturers adhering to stringent global regulatory standards. Pharmaceutical companies must prioritize robust supplier qualification, geographical diversification, and comprehensive quality agreements to ensure a stable and compliant supply. The market is characterized by price sensitivity driven by the generic nature of the product, necessitating efficient production and strategic sourcing. Proactive risk management, including mitigation for regulatory, geopolitical, and quality-related disruptions, is critical for maintaining uninterrupted product availability.

FAQs

1. What are the primary indications for drugs utilizing deferasirox API? Deferasirox API is primarily used in the treatment of chronic iron overload, particularly in patients with conditions requiring frequent blood transfusions such as thalassemia, sickle cell disease, and other myelodysplastic syndromes.

2. Are there any major supply chain vulnerabilities specific to deferasirox API production? Key vulnerabilities include reliance on specific geographic regions for manufacturing (primarily India and China), potential raw material price volatility, and the inherent risks associated with global logistics and geopolitical instability.

3. What is the role of regulatory bodies like the FDA and EMA in the deferasirox API supply chain? These bodies establish and enforce Current Good Manufacturing Practices (cGMP) that API manufacturers must adhere to. They review Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) submitted by API manufacturers, which are critical for the approval of finished drug products. They also conduct inspections of manufacturing facilities.

4. How does the expiration of patents for Exjade impact the deferasirox API market? Patent expiration allows for the introduction of generic versions of Exjade, leading to increased competition among finished drug product manufacturers. This, in turn, drives demand for deferasirox API from multiple generic API suppliers and can lead to price pressures for API manufacturers.

5. What are the key quality control parameters that pharmaceutical companies monitor for deferasirox API? Key parameters include API purity (assay), identification, levels of specified and unspecified impurities, residual solvents, heavy metals, water content, and physical characteristics such as particle size distribution, all of which must meet pharmacopoeial standards and specifications defined in regulatory filings and quality agreements.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry [Relevant cGMP guidance documents available on FDA website]. Retrieved from [FDA website] [2] European Medicines Agency. (n.d.). Scientific Guidelines [Relevant cGMP and ASMF guidance documents available on EMA website]. Retrieved from [EMA website] [3] Pharmaceutical manufacturers' annual reports and public disclosures (e.g., Cipla, Lupin, Sun Pharma, Dr. Reddy's, Zydus Lifesciences). (Various years). [4] Industry analysis reports from pharmaceutical market research firms. (Various years). [5] Chemical Abstracts Service (CAS) database for deferasirox (CAS Number: 201529-34-2) and related synthesis pathways.